



Clathrin-Mediated Endocytosis Regulates a Balance between Opposing Signals to Maintain the Pluripotent State of Embryonic Stem Cells

Yadavalli V. Narayana,^{1,2} Chetan Gadgil,³ Ridim D. Mote,¹ Raghav Rajan,⁴ and Deepa Subramanyam^{1,*}

¹National Centre for Cell Science, SP Pune University, Ganeshkhind, Pune 411007, India

²Savitribai Phule Pune University, Ganeshkhind, Pune 411007, India

³Chemical Engineering Department, National Chemical Laboratory, Dr. Homi Bhabha Road, Pune 411008, India

⁴Indian Institute of Science Education and Research, Dr. Homi Bhabha Road, NCL Colony, Pune 411008, India

*Correspondence: deepa@nccs.res.in

<https://doi.org/10.1016/j.stemcr.2018.11.018>

SUMMARY

Endocytosis is implicated in the maintenance of embryonic stem cell (ESC) pluripotency, although its exact role and the identity of molecular players remain poorly understood. Here, we show that the clathrin heavy chain (CLTC), involved in clathrin-mediated endocytosis (CME), is vital for maintaining mouse ESC (mESC) pluripotency. Knockdown of *Cltc* resulted in a loss of pluripotency accompanied by reduced E-cadherin (E-CAD) levels and increased levels of transforming growth factor β (TGF- β) and extracellular signal-regulated kinase (ERK) signaling. We demonstrate that both E-CAD and TGF- β receptor type 1 (TGF- β R1) are internalized through CME in mESCs. While E-CAD is recycled, TGF- β R1 is targeted for lysosomal degradation thus maintaining inverse levels of these molecules. Finally, we show that E-CAD interacts with ERK, and that the decreased pluripotency upon CME loss can be rescued by inhibiting TGF- β R, MEK, and GSK3 β , or overexpressing E-CAD. Our results demonstrate that CME is critical for balancing signaling outputs to regulate ESC pluripotency, and possibly cell fate choices in early development.

INTRODUCTION

Mammalian development is an exquisitely controlled process involving the concerted action of numerous signaling pathways and cellular processes. Embryonic stem cells (ESCs) isolated from the inner cell mass of the blastocyst represent a wonderful model system to follow developmental decisions and cell fate transitions *in vitro* (Evans, 2011; Evans and Kaufman, 1981; Martin, 1981). Recent reports have demonstrated that endocytosis plays a role in regulating the acquisition, as well as the maintenance of the pluripotent state (Dambournet et al., 2018; Li et al., 2010; Mote et al., 2017; Qin et al., 2014; Subramanyam et al., 2011). Endocytosis is a fundamental eukaryotic process, wherein membrane-bound proteins are trafficked to different compartments of the cell depending on their function, with the help of small GTPases called RABs (Doherty and McMahon, 2009; Traub, 2009).

Endocytosis is known to play a role in cell fate specification during early metazoan development (De Renzis et al., 2006; Fabrowski et al., 2013; Kawamura et al., 2012; Song et al., 2013). However, the exact mechanistic role played by endocytosis in the regulation of early mammalian development remains to be elucidated.

To this end, we undertook a small interfering RNA (siRNA) screen in mouse ESCs (mESCs), wherein transcripts encoding for endocytic components were depleted, and the pluripotency of ESCs was assessed. We found that knocking down clathrin heavy chain (*Cltc*), a major coat protein required for clathrin-mediated endocytosis (CME), resulted in a decrease

in mESC pluripotency. Further, we show that CME regulated mESC pluripotency by trafficking two opposing molecular players, namely E-cadherin (E-CAD or CDH1) and transforming growth factor β receptor type 1 (TGF- β R1). In mESCs, E-CAD is recycled back to the membrane after internalization, while TGF- β R1 is targeted to the lysosome for degradation. We further discovered a novel interaction between E-CAD and extracellular signal-regulated kinase (ERK) in mESCs, and found that loss of CME resulted in elevated ERK signaling. β -CATENIN levels were also reduced upon loss of CME. A decrease in CME thus caused an imbalance between key signaling pathways, resulting in a loss of pluripotency. Our results demonstrate that trafficking of molecules via endocytosis is required to maintain the pluripotent state and identity of mESCs, and that a change in endocytic thresholds may facilitate cell fate transitions.

RESULTS

Clathrin Heavy Chain Is an Essential Molecule for Maintaining the Pluripotency of mESCs

While the contribution of endocytosis to the state of pluripotency has been minimally described over the last few years (Dambournet et al., 2018; Li et al., 2010; Mote et al., 2017; Qin et al., 2014; Subramanyam et al., 2011), a systematic study looking at specific endocytic elements that are intimately involved in the maintenance of ESC pluripotency is lacking. We undertook an unbiased, small-scale siRNA-based screen, targeting 112 different






Figure 1. CME Is Required for the Maintenance of mESC Pluripotency and Self-Renewal

(A) Dot plot showing the results of the endocytic siRNA screen in mESCs, based on AP staining. Knockdowns resulting in a significant decrease in AP staining are marked in blue, while those resulting in an increase in AP staining are shown in red.

(B) Bright-field images show AP staining and morphology of mESCs 2 days post *Cltc* knockdown, or expression of *K44A Dnm* (*K44A*). Scale bar, 50 μ m. NTi, non-targeting siRNA control; *Cltc*, *Cltc* siRNA; control, vector control.

(C) Bar graph showing mESC colony number, 3 days post indicated conditions.

(D and E) Line graph showing the proliferation rate of (D) mESCs and (E) MEFs over 3 days post indicated conditions.

(F) Cell-cycle analysis of mESCs and MEFs 3 days post indicated conditions. Bar graph shows the percent of cells in G1, S, and G2 phases of the cell cycle for both mESCs and MEFs.

(G) Bar graph showing the expression of pluripotency markers in mESCs under indicated conditions relative to control (n = 3). Control is shown as a dotted line at 1.

(H) Bar graph showing the expression of differentiation markers in embryoid bodies generated from *Cltc* knockdown mESCs by qRT-PCR analysis (n = 3). SCi, scrambled shRNA control; *Cltc*, *Cltc* shRNA.

Error bars represent mean \pm SD from three independent experiments (n = 3). *p < 0.05; **p < 0.01; ***p < 0.001 by two-tailed Student's t test.

components of the endocytic machinery. Efficiency of individual pools of siRNA was not determined. Levels of alkaline phosphatase (AP) activity, a marker of ESC pluripotency (Wang et al., 2013), was used as a readout based on the analysis described in the Experimental Procedures. High-throughput screening based on detection of AP was performed 4 days after transfection of siRNAs into mESCs. Knockdown of five genes resulted in a significant increase in AP staining (shown as red bars), while knockdown of two genes resulted in a significant decrease in AP staining (shown in blue) (Figure 1A). We were specifically interested in understanding the role of endocytic genes in the maintenance of pluripotency, and hence focused on genes

whose knockdown resulted in a loss of AP staining. One such gene was the clathrin heavy chain (*Cltc*) (Figure 1A).

Cltc encodes for the heavy chain of clathrin, which is an integral component of the clathrin triskelion, which forms the clathrin coat during CME (Kirchhausen et al., 2014; McMahon and Boucrot, 2011). The clathrin coat stabilizes endocytic structures through polymerization at the sites of endocytosis (Saffarian et al., 2009; Tebar et al., 1996), followed by scission of the clathrin-coated pit with the help of the small GTPase, Dynamin (Ferguson and De Camilli, 2012).

We validated the screen results by generating independent endoribonuclease-prepared siRNAs (esiRNAs) (Kittler




Figure 2. E-CAD Trafficking Is Required to Maintain mESC Pluripotency

(A) Western blot showing E-CAD levels upon knockdown of *Cltc* in mESCs.

(B and C) Representative confocal micrographs showing the co-localization of E-CAD with CLTC (B) and RAB11 (C). Scale bars, 7.5 μ m (B) and 10 μ m (C).

(D) Representative confocal micrographs showing the increased localization of E-CAD with RAB11-positive recycling endosomes in the presence of the E-CAD neutralizing antibody, DECMA1 (1 hr treatment). Scale bars, 10 μ m (top panel) and 25 μ m (lower panel). Mouse IgG was used as a control.

(legend continued on next page)



et al., 2007), targeting *Cltc*, which showed a significant reduction of CLTC protein in mESCs (Figure S1A). Knockdown of *Cltc* resulted in a decrease in the uptake of labeled transferrin (a well-studied cargo for CME) (Kirchhausen et al., 2014) into mESCs, indicative of a block of CME (Figures S1B and S1C). As previously reported, transferrin uptake was also significantly reduced upon introduction of the dominant negative mutant of Dynamin, *K44A Dnm* (Bitoun et al., 2009; Herskovits et al., 1993), in mESCs (Figures S1D and S1E). We found that blocking CME in mESCs through either the knockdown of *Cltc*, or upon overexpression of *K44A Dnm*, resulted in a decrease in AP staining (Figure 1B), colony-forming ability (Figure 1C), a reduction in the proliferation rate (Figure 1D), and an altered cell-cycle profile with increased number of cells in G1 (Figure 1F). However, changes in the proliferation, or cell-cycle profile were not observed in terminally differentiated mouse embryonic fibroblasts (MEFs) upon blocking CME (Figures 1E and 1F). Reduced CME resulted in a significant decrease in the expression of pluripotency markers (Figures 1G, S1F, and S1H), and an increase in the expression of differentiation markers corresponding to all three germ layers (Figures 1H, S1G, and S1I). However, no induction of apoptosis was observed upon blocking CME (Figure S1J). Teratomas generated from *Cltc* knockdown cells were smaller compared with those generated from wild-type cells (Figure S1K), while containing structures corresponding to all three germ layers (Figure S1L). However, teratomas generated from *Cltc* knockdown mESCs displayed excessive hemorrhage, and appeared to have a greater bias toward mesodermal differentiation (Figure S1L). Our results thus demonstrate that CME plays an important role in maintaining the pluripotent state of mESCs.

Clathrin-Dependent Endocytosis of E-CAD Maintains mESC Pluripotency

Interestingly, the knockdown of *Cltc*, or the introduction of *K44A Dnm* in mESCs, resulted in a striking phenotype, with

cells showing a dispersed and flattened morphology and loss of cell-cell contacts, reminiscent of the phenotype of ESCs lacking *E-cad* (Redmer et al., 2011) (Figures 1B and S2). These morphological features are different from normal mESCs, which grow in tight, three-dimensional, domed colonies that are AP positive (Figure 1B). Indeed, we found that E-CAD levels were decreased upon blocking CME in mESCs (Figures 2A, S3A, S3B, S4A, and S4B). In addition, E-CAD levels were also depleted from the plasma membrane under *Cltc* knockdown conditions (Figure S3B).

The transmembrane, Ca^{2+} -dependent protein, E-CAD, is known to act by maintaining cell contacts through the formation of adherens junctions (Leckband and de Rooij, 2014). It is involved in maintenance of the pluripotent state of mESCs (Redmer et al., 2011), and is required for normal mammalian development (Larue et al., 1994; Stephenson et al., 2010). Trafficking of E-CAD has been shown to be essential for the generation and turnover of cell-cell contacts in the context of vertebrate development (Nanes and Kowalczyk, 2012; Song et al., 2013). However, it is unclear whether E-CAD undergoes endocytosis in mESCs and, if so, which pathways of intracellular trafficking are utilized, and whether this impacts pluripotency.

We observed that E-CAD co-localized with CLTC (Figures 2B and S3D), and co-immunoprecipitated with the clathrin adaptor AP2 complex subunit, $\text{AP2}\alpha$ (Figure S3C), confirming that E-CAD indeed associates with the CME machinery in mESCs. E-CAD localization was also abundantly detected in RAB11-positive recycling endosomes (Figures 2C and S3E). RAB7-positive late endosomes and LAMP2-positive lysosomes, which target cargo for lysosomal degradation, were largely devoid of E-CAD (Figures S3F and S3G).

E-CAD was predominantly present on the membrane in mESCs (Figure 2B). We disrupted its normal localization through two approaches: (1) treatment with an E-CAD neutralizing antibody (DECMA1), which prevents the dimerization of E-CAD, resulting in its internalization; and (2) treatment with EDTA, a metal ion chelating agent that chelates the extracellular Ca^{2+} , preventing E-CAD

(E) Scatterplot showing the quantitation of E-CAD levels, membrane versus cytoplasmic, in the presence of the E-CAD neutralizing antibody, DECMA1. ** $p < 0.01$ by two-tailed Student's t test.

(F) Graph showing levels of pluripotency marker genes by qRT-PCR analysis in mESCs treated with the E-CAD neutralizing antibody, DECMA1 or mouse IgG (24 hr treatment). * $p < 0.05$; ** $p < 0.01$ by two-tailed Student's t test.

(G) Representative confocal micrographs showing E-CAD accumulation in RAB11-positive endosomes in mESCs treated with BAF-A1. DMSO was used as a vehicle control. Scale bars, 25 μm (top panel) and 10 μm (lower panel).

(H) Scatterplot showing the quantitation of E-CAD levels, membrane versus cytoplasmic; in mESCs treated with BAF-A1. *** $p < 0.001$ by two-tailed Student's t test.

(I) Graph showing levels of pluripotency marker genes by qRT-PCR analysis in mESCs treated with BAF-A1 or DMSO.

(J) Graph showing levels of pluripotency marker genes by qRT-PCR analysis upon *Rab11* knockdown in mESCs. SCi, scrambled shRNA control; *Rab11i*, *Rab11* shRNA.

Error bars represent mean \pm SD from three independent experiments ($n = 3$). * $p < 0.05$; ** $p < 0.01$; *** $p < 0.001$ by two-tailed Student's t test.



dimerization. Treatment of mESCs with either DECMA1 or EDTA resulted in a loss of cell-cell contacts and decreased E-CAD on the cell surface (Figures 2D, 2E, S3H, and S3I). This was accompanied by a decrease in the expression of pluripotency marker genes (Figures 2F and S3J), similar to what was previously observed in *E-cad* null mESCs (Redmer et al., 2011).

Treatment of mESCs with DECMA1, or EDTA, resulted in increased accumulation of E-CAD in RAB11-positive recycling endosomes (Figures 2D, 2E, S3H, and S3I). To determine whether recycling of E-CAD was essential for the pluripotency of mESCs, we knocked down *Rab11* (Figure S3K), or blocked endosomal recycling by treating cells with the pharmacological inhibitor, Bafilomycin A1 (vesicular ATPase inhibitor that blocks endocytic recycling) (Presley et al., 1997). This resulted in an increased accumulation of E-CAD in RAB11-positive endosomes (Figures 2G and 2H) and a decrease in the expression of pluripotency marker genes (Figures 2I and 2J). Taken together, our results imply that the normal membrane localization, internalization through CME, and the recycling of E-CAD are essential for the pluripotency of mESCs. Thus, the normal trafficking of E-CAD is imperative to maintain the pluripotency of mESCs.

CME Suppresses TGF- β /SMAD Signaling to Maintain E-CAD Expression and mESC Pluripotency

The loss of CME resulted in a dramatic phenotype, with loss of cell-cell contacts and a decrease in levels of *E-cad*/E-CAD at both the transcript and protein levels (Figures 2A, 3A, S2, S3A, S4A, and S4B), highly reminiscent of the action of a core epithelial-mesenchymal transition driver, TGF- β signaling (Lamouille et al., 2014; Nieto et al., 2016; Xu et al., 2009). Increased TGF- β signaling is associated with the differentiation of ESCs (Fei et al., 2010), and is also known to play a negative role during somatic cell reprogramming (Ichida et al., 2009; Li et al., 2011; Subramanyam et al., 2011). Activation of the TGF- β /SMAD signaling pathway results in the expression of transcription factors *Snai1* (Snail), *Snai2* (Slug), and *Zeb1*, which transcriptionally repress *E-cad* (Xu et al., 2009). Blocking CME resulted in the stabilization of TGF- β R1 levels accompanied by elevated levels of active TGF- β /SMAD signaling, determined by phospho-SMAD2/3 levels (Figures 3B, 3C, S4C, S4E, and S4F). Blocking CME resulted in increased expression of *Snai1*, *Snai2*, *Zeb1*, and *Cdh2* in mESCs (Figures 3D and S4D).

TGF- β R1 co-localized with CLTC and the late endosomal marker, RAB7 (Figures 3E, 3F, S4G, and S4H), suggesting that TGF- β R1 is internalized through CME and targeted for lysosomal degradation. Minimal to no co-localization was observed with RAB11, suggesting minimal or no recycling of TGF- β R1 in mESCs (Figure S4I). To determine whether TGF- β R1 was indeed targeted for lysosomal degra-

ation, we used siRNAs to knock down *Rab7* (Figure S4J). We observed an accumulation of LC3-2, a protein that is degraded in the lysosome (Figure S4K), indicating a block in lysosomal degradation on loss of *Rab7*. This was accompanied by an increase in the levels of TGF- β R1 (Figure 3G), pSMAD2/3 (Figure 3H), and mesenchymal markers (Figure 3I). The mesenchymal genes *Snai1*, *Snai2*, and *Zeb1* are known to transcriptionally repress *E-cad* expression. Indeed, knockdown of *Rab7* resulted in a decrease in *E-cad*/E-CAD expression, presumably through a feedback loop involving downstream targets of TGF- β R1 signaling (Figures 3J and S4K), similar to what was observed upon *Cltc* knockdown. These observations were further validated by treatment of mESCs with the lysosomal inhibitor, chloroquine, resulting in increased levels of LC3-2 (Figure S4L), TGF- β R1 (Figure S4M), and pSMAD2/3 (Figure S4N). Blocking lysosomal degradation also resulted in a decrease in E-CAD levels (Figure S4O), similar to what we observed upon knockdown of *Rab7* (Figure S4K). Together these results show that CME negatively regulates TGF- β /SMAD signaling to maintain E-CAD expression and the pluripotency of mESCs.

Based on these observations, we constructed a mathematical model for the inter-relationships between TGF- β signaling, E-CAD, and CLTC (Figure 3K; Table S1). Keeping all other parameters constant, clathrin depletion was modeled by decreasing the parameter for clathrin levels by 10-fold. The depletion of clathrin resulted in a decrease in E-CAD levels, due to an increase in TGF- β signaling, consistent with the experimental observations. In addition, the model predicted an initial transient increase in membrane-bound E-CAD (not shown here) upon clathrin depletion, which is explained as the effect of decreased internalization resulting from the depletion of CLTC. We further used the model to ask whether decreasing TGF- β signaling upon clathrin depletion could restore the cell to its original state. We simulated a decrease in TGF- β signaling following *Cltc* depletion, by changing the parameter *Kitmec* (Table S1), which changes the sensitivity of the E-CAD formation rate to TGF- β R levels by 5-fold, keeping other parameters constant. From the simulation results (“reduced clathrin and TGF- β R dependence” set) we predicted that this leads to a restoration of E-CAD (membrane bound), and possibly even a higher level due to the reduced internalization even though there is no effect on the membrane-bound TGF- β R levels (Figure 3L).

Based on the constructed model, we predicted that perhaps the normal balance of signaling could be restored in mESCs in the absence of CME by blocking the aberrant increase in TGF- β /Smad signaling. To test this, we treated *Cltc*-depleted mESCs with TGF- β R1 kinase inhibitors, RepSox (Ichida et al., 2009), or SB431542. Inhibition of TGF- β /Smad signaling resulted in a partial rescue of the




Figure 3. CME Promotes Degradation of TGF-βR1 to Maintain E-CAD Levels in mESCs

(A) Graph showing levels of the *E-cad* transcript by qRT-PCR analysis upon knockdown of *Clcti* in mESCs. NTi, non-targeting siRNA control; *Clcti*, *Clcti* siRNA.

(B and C) Western blots showing TGF-βR1 (B), pSMAD2/3, and total SMAD2/3 (C) levels in mESCs, 72 hr post *Clcti* knockdown.

(D) Graph showing levels of indicated genes by qRT-PCR analysis after 3 days of *Clcti* knockdown in mESCs.

(E and F) Representative micrographs showing the co-localization between CLTC and TGF-βR1 (E) and between TGF-βR1 and RAB7 in mESCs (F). Scale bar, 10 μm.

(G and H) Western blots showing TGF-βR1, pSMAD2/3, and total SMAD2/3 levels 72 hr post *Rab7i* knockdown in mESCs. *Rab7i*, *Rab7* siRNA.

(I) Graph showing levels of indicated genes by qRT-PCR analysis upon knockdown of *Rab7* in mESCs.

(J) Graph showing levels of *E-cad* by qRT-PCR analysis upon knockdown of *Rab7* in mESCs.

(K) Construction of a model to show the inter-relationships between TGF-βR, E-CAD, and CLTC in mESCs. E, E-CAD; T, TGF-βR; m, membrane; c, cytoplasm; e, endosome; r, recycling endosome; l, lysosome.

(L) Graph showing levels of E-CAD and TGF-βR based on simulation of the constructed model. WT (wild-type) represents the pre-treatment concentrations of membrane-bound TGF-βR and E-CAD. The “reduced clathrin” set shows the steady-state values following clathrin depletion. The “reduced clathrin and TGF-βR dependence” set is obtained by simulating a decrease in TGF-β signaling following CLTC depletion, by changing the parameter *Kitmec*, which changes the sensitivity of the E-CAD formation rate to TGF-βR levels by 5-fold, keeping other parameters constant.

Error bars represent mean ± SD from three independent experiments (n = 3). *p < 0.05; **p < 0.01; ***p < 0.001 by two-tailed Student’s t test.

phenotype with restoration of cell-cell contacts of mESCs, along with increased AP activity (Figure 4A), OCT3/4 and E-CAD expression (Figures 4B and 4C). The overexpression of *E-cad* alone also (Figure 5A) resulted in a rescue of pluripotency in the background of decreased CME (Figures 5B and 5C).

These results indicate that CME plays a vital role in regulating the balance between opposing signals such as E-CAD (pro-pluripotency) and TGF-β (pro-differentiation) in ESCs.

E-CAD is also known to associate with other proteins such as β-CATENIN (Nanes and Kowalczyk, 2012). β-CATENIN signaling is required for the maintenance of mESC pluripotency and self-renewal (Anton et al., 2007; Miyabayashi et al., 2007). Indeed we found that as reported earlier (Nanes and Kowalczyk, 2012), β-CATENIN associated with E-CAD in mESCs (Figure S5A). Knockdown of *Clcti* resulted in decreased β-CATENIN levels (Figure S5B) and enhanced phospho-β-CATENIN levels (Figure S5B),




Figure 4. Effect of *Cltc* Knockdown in mESCs Can Be Partially Rescued by Inhibiting TGF- β Signaling

(A) Bright-field micrographs showing AP staining and morphology of *Cltc* knockdown mESCs in the presence of TGF- β inhibitors RepSox or SB431542 (SB). Scale bar, 50 μ m. (B) Immunofluorescence micrographs showing OCT3/4 and E-CAD staining upon RepSox or SB431542 (SB) treatment in mESCs with *Cltc* knockdown. Scale bar, 50 μ m. (C) Bar graph showing the quantitation of OCT3/4 and E-CAD-positive mESC colonies upon RepSox or SB431542 (SB) treatment in *Cltc* knockdown mESCs. Error bars represent mean \pm SD from three independent experiments (n = 3). **p < 0.01 by two-tailed Student's t test. One-way ANOVA with *post-hoc* Tukey-Kramer test was used.

suggestive of it being targeted for degradation (Perez-Morano and Fuchs, 2006). In addition, we also observed enhanced levels of active phospho-ERK1/2 levels (Figure S5E), which is associated with the differentiation of mESCs toward the neural and mesodermal lineages (Kunath et al., 2007; Stavridis et al., 2007). Interestingly, we also observed for the first time an interaction between E-CAD and ERK in mESCs (Figures S5C and S5D), indicating that E-CAD may function as a hub to regulate the activity of other proteins involved in the pluripotency of mESCs.

The naïve state of ESCs is maintained by culturing them in a media containing mitogen-activated protein kinase (MEK) and glycogen synthase kinase 3 β (GSK3 β) inhibitors (Ying et al., 2008). We therefore sought to determine whether the loss of pluripotency upon *Cltc* knockdown could be rescued by treatment with either the MEK inhibitor, or the GSK3 β inhibitor (1i), or both (2i). Indeed, we found that the knockdown of *Cltc* in mESCs cultured in MEK inhibitor or 2i medium did not result in a significant decrease in pluripotency (Figures S5F and S5G), suggesting that the elevation in MEK signaling alone, or in combination with decreased β -CATENIN levels in the absence of CME, plays a significant role in exiting the pluripotent state.

In summary, our data indicate that CME plays a crucial role in maintaining a fine balance between antagonistic signaling pathways, such as TGF- β /SMAD, ERK, β -CATENIN, and E-CAD. CME is required for the internalization and recycling of E-CAD, and for the lysosomal degradation of TGF- β R1 in mESCs. Any disruption in this trafficking mechanism leads to dominance of the differentiation signal, TGF- β , along with elevated levels of phospho-ERK, and reduced levels of β -CATENIN, resulting in a cell fate change. We find that repression of the differentiation signal is sufficient to some extent to restore the pluripotent state. Our results thus demonstrate that CME is required for the normal pluripotent state of mESCs, and that altering CME levels may permit ESCs to exit the pluripotent state.

DISCUSSION

While endocytosis plays a major role in metazoan development, it remains largely unknown as to whether and how it can function as a regulator of cell fate decisions. Here we demonstrate that CME functions as a novel regulator of ESC pluripotency. Decrease in the level of CME in ESCs results in an exit from the pluripotent state. We further




Figure 5. Effect of *Cltc* Knockdown in mESCs Can Be Partially Rescued by Overexpressing *E-cad*

(A) Western blot showing the overexpression of E-CAD in mESCs post transfection with the pEF1-*E-cad* vector. The EF1 empty vector is used as a control.

(B) Representative micrographs showing the morphology of mESCs in the presence of empty vector (EF1), and vector-expressing *E-cad* (pEF1-*E-cad*) in combination with either NTi or *Cltc*. Scale bar 50 μ m.

(C) Bar graph showing the levels of pluripotency marker genes in the presence of the empty vector or upon *E-cad* overexpression. EF1, empty vector; *E-cad*, EF1-*E-cad* vector; NTi, non-targeting siRNA control; *Cltc*, *Cltc* siRNA. Error bars represent mean \pm SD from three independent experiments ($n = 3$). * $p < 0.05$; ** $p < 0.01$ by two-tailed Student's t test. One-way ANOVA with *post-hoc* Tukey-Kramer test was used.

demonstrate that, in ESCs, CME facilitates the internalization and recycling of E-CAD, while simultaneously being required for the internalization and lysosomal targeting of TGF- β R. It is well appreciated that cell-cell adhesion mediated by E-CAD is crucial for maintaining mESC self-renewal (Murray et al., 2013; Redmer et al., 2011; Soncin et al., 2011). Our findings show that the internalization and recycling of E-CAD via CME is crucial to maintain the stem cell state of mESCs. Although the mechanistic underpinnings of this regulation are unclear, based on our data and previous studies with the NOTCH receptor and GPCRs (Windler and Bilder, 2010; Eichel et al., 2016) we speculate that E-CAD trafficking via CME may facilitate its transition through different intracellular compartments to either undergo conformational changes or association with other proteins, ultimately resulting in an altered signaling output. While RAP1 has been previously described to play a role in the recycling of E-CAD, it is unclear as to whether this is dependent on CME (Li et al., 2010). Our data are also strengthened by our observation that E-CAD is enriched in ESC-derived endosomes (Narayana et al. unpublished data). A similar mechanism has also been described with pSTAT3 in mESCs, where its association with the endosomal protein ASRIJ regulates STAT3 signaling, as well as the expression of pluripotency genes (Sinha et al., 2013). In addition to the recycling of E-CAD, CME also plays a major role in maintaining the expression of *E-cad* by lysosomal degradation of the TGF- β receptor. Earlier studies in non-stem cells show that TGF- β receptors were recycled via CME (Chen, 2009; Hayes et al., 2002; Mitchell et al., 2004). Previous studies have also demonstrated that CME is involved in enhancing

signals downstream of the TGF- β receptor, while the caveolin-mediated endocytic route targets these receptors for degradation (Di Guglielmo et al., 2003; Scita and Di Fiore, 2010), indicating a requirement for specific compartmentalization of the same receptor to achieve opposing outcomes. We have previously demonstrated that caveolin-mediated endocytosis is largely absent in mESCs (Mote et al., 2017), and here we demonstrate that CME promotes the lysosomal degradation of the TGF- β receptor. Such varying utilizations of trafficking pathways in the context of the same receptor may be a reflection of the specific state of a cell, and an attempt to maintain a balance in signaling outcomes to support a particular cell fate. While it remains elusive as to how CME is involved in sorting a specific cargo to different compartments in stem versus non-stem cells, our findings show that CME balances opposing signals to maintain ESC pluripotency by sorting molecules to different compartments.

In addition, we also see that both β -CATENIN and ERK associate with E-CAD, implicating yet another layer of regulation in ESCs, linked to E-CAD. It remains to be seen whether the activity of ERK and β -CATENIN are dependent on the internalization of E-CAD. Our results demonstrate that we could rescue the decrease in pluripotency caused by the loss of CME by either inhibiting the TGF- β or MEK signaling pathway, or by overexpressing *E-cad*, indicating that CME does indeed regulate the activity of multiple signaling pathways and molecules in mESCs. Together, our data demonstrate that an intact trafficking machinery is essential for regulating the activity of key signaling molecules, all of which are intimately linked to the pluripotent state of a stem cell.



It is well established that CME is one of the major routes of endocytosis in differentiated cells (Doherty and McMahon, 2009; Traub, 2009). Recent results comparing the rate of CME between human ESCs and differentiated cells show that the rate of endocytosis decreases as stem cells differentiate (Dambournet et al., 2018). Further, this was also accompanied by changes in types of clathrin coats that were observed as ESCs underwent differentiation. This is in line with our observation that ESCs differentiate upon reduction of CME. In addition, our data suggest that a temporary reduction of CME, or a fine-tuning of levels of endocytosis in a cell that possesses the potential to switch fate, such as a stem cell, can provide a novel handle to regulate cell fate changes. Further studies in understanding the mechanistic role of endocytosis will expand our understanding about the role of cellular trafficking in stemness, cell fate decisions and development.

EXPERIMENTAL PROCEDURES

Cell Culture, Chemical Treatments, Plasmids, and Antibodies

V6.5 and R1 mESCs were cultured on 0.2% gelatin-coated plastic tissue culture dishes (Corning), and cultured in media containing knockout DMEM (Invitrogen), 15% fetal bovine serum (Invitrogen), 2 mM L-glutamate (Invitrogen), 1× penicillin/streptomycin (Invitrogen), 1 mM non-essential amino acids (Invitrogen), 100 μM β-mercaptoethanol (Invitrogen), and 5,000 U leukemia inhibitory factor (LIF) (ESC medium). MEFs were isolated from embryonic day 13.5 stage mouse embryos from the CF1 strain of mice. Inhibitors and chemicals were used as follows: chloroquine (Sigma) was used at 100 μM final concentration; RepSox (Sigma) 25 μM final concentration; SB431542 (Sigma) 5 μM final concentration; PD0325901 (Sigma) was used at 0.1 μM final concentration; CHIR99021 (Sigma) was used at 0.3 μM final concentration; Bafilomycin A1 (Sigma) 1 μM final concentration; EDTA (pH 8.0), 2.5 μM final concentration. *K44A Dynammin2-GFP* mutant was obtained from Addgene (no. 34687). Empty *pEGFP N1* vector was used as a control. The following antibodies were used at the appropriate concentrations: CLTC (sc-6579, Santa Cruz, goat), TGF-βR1 (sc-398, Santa Cruz, rabbit), NANOG (sc-30328, Santa Cruz, goat), SMAD2/3 (sc-7960, Santa Cruz, mouse), RAB7 (sc-81922, Santa Cruz, rabbit), OCT3/4 (no. 2849, Cell Signaling Technology, rabbit), E-CAD (no. 3195, Cell Signaling Technology, rabbit), pSMAD2/3 (no. 8828, Cell Signaling Technology, rabbit), SOX2 (ab97951, Abcam, rabbit), E-CAD (no. 610182, BD Transduction Laboratories, mouse), RAB11 (no. 610657, BD Transduction Laboratories, mouse), CLTC (no. 610500, BD Transduction Laboratories, mouse), TUBULIN (T5168, Sigma, mouse), RAB5 (no. 3547, Cell Signaling Technology, rabbit), RAB7 (no. 9367, Cell Signaling Technology, rabbit), GAPDH (no. SC25778, Santa Cruz, rabbit), Na,K⁺ ATPASE (no. 21713, Santa Cruz, goat), LC3 1/2 (no. 12741, Cell Signaling Technology, rabbit), LAMP2 (ab13542, Abcam, rat). E-CAD neutralizing antibody (DECMA-1, Abcam ab11512) was used at 5 μg/mL final concentration. Rat

immunoglobulin G (IgG) was used as an antibody control. For imaging, cells were treated with the antibody for 1 hr, and for pluripotency assays, 24 hr in ESC media. Mouse *E-cad* open reading frame was amplified from cDNA and cloned into Ecor1 and Not1 sites of pEF1/myc-His vector (a gift from Dr. Ramkumar Sambasivan). Transfections were performed using Lipofectamine 2000 (no. 11668019, Invitrogen) according to the manufacturer's instructions. All experiments were performed using V6.5 ESCs. Experiments where R1 ESCs were used are clearly indicated.

Lentivirus Production and Infection

Piko.1 scrambled, *Cltc*, and *Rab11* small hairpin RNA (shRNA) vectors (obtained from shRNA Resource Center, Indian Institute of Science, Bangalore) were co-transfected with psPAX2 (Addgene, no. 12260), pMD2.G (Addgene, no. 12259) in HEK293T cells using FuGENE HD (no. E2311, Promega). Viral supernatants were harvested and used for infection 48 hr post transfection.

qRT-PCR

Total RNA was isolated using TRIzol (Invitrogen) and quantified using a NanoDrop Spectrophotometer (Thermo Fisher Scientific). For mRNA amplification, 1 μg RNA was treated with DNaseI (Invitrogen), and reverse transcribed using the Superscript III kit (Invitrogen) using random hexamers. Total cDNA thus obtained was diluted 1:10 and 1 μL was used for qRT-PCR using gene-specific primers and Power SYBR Green PCR Master Mix (Applied Biosystems). Primers sets are listed in Table S2. For qRT-PCR analysis, mRNA expression is normalized to *GAPDH* and represented relative to control or non-targeting siRNA.

Colony Counting and Cell Doubling Time

A total of 50,000 mESCs were plated in a 6-well plate and transfected the next day with *Cltc* esiRNA. Colonies were counted on day 4. For determination of cell doubling time, 20,000 cells were plated in a 24-well dish and transfected with *Cltc* esiRNA next day. Post transfection, cells were counted every 24 hr.

Cell-Cycle Analysis

Cells (20,000) were grown in a 24-well dish and treated as indicated. After 72 hr, cells were trypsinized and washed twice with PBS, fixed in 95% ethanol at 4°C overnight, stained with propidium iodide (10 μg/mL) and RNase A (10 μg/mL), and 2 mM MgCl₂. Stained cells were analyzed on a BD FACS Calibur.

Alkaline Phosphatase Staining

ESCs were transfected with siRNAs or the mentioned plasmid, and stained for AP activity using a kit (Vector Laboratories), as per manufacturer's instructions.

esiRNA Preparation and Transfection

Template for esiRNA production against specific genes was prepared by PCR amplification from mESC or MEF cDNA. *In vitro* transcription was performed using T7 RNA polymerase, followed by digestion of the double-stranded RNA using RNase III (Fazzio et al., 2008; Kittler et al., 2007). esiRNAs were transfected into ESCs using DharmaFECT 1 transfection reagent (Dharmacon).



After 72 hr, cells were lysed in TRIzol for RNA, or in RIPA lysis buffer to prepare whole-cell protein extract. Non-targeting esiRNA was prepared using GFP as a template in all experiments.

Western Blotting

Protein lysates were separated on SDS-PAGE, blotted onto a polyvinylidene fluoride membrane, and blocked with 5% BSA or skimmed milk. Primary antibodies were used at specific concentrations overnight, followed by incubation with the appropriate secondary antibody.

Immunocytochemistry and Imaging

mESCs were cultured on glass coverslips coated with 0.2% gelatin. Cells were fixed with 4% paraformaldehyde (PFA) for 10 min at 37°C, followed by blocking and permeabilization using 5% BSA containing 0.1% Triton X-100. Incubation with primary antibody was done overnight at 4°C, followed by washing and incubation with secondary antibody for 1 hr at room temperature, and washing and mounting using VECTASHIELD (Vector Laboratories). All confocal imaging was done using the Leica SP5 confocal microscope, and imaged using a 63× 1.4 NA objective. Bright-field images were taken using Nikon Eclipse Ti2 microscope with either the 20× or 10× objective.

Teratoma Formation Assay

mESCs (25×10^5) stably expressing scrambled or *Cltc* shRNA were suspended in 50 μ L knockout DMEM and 10 μ L of Matrigel. Nude mice were anesthetized with diethyl ether and 60 μ L of cell suspension was injected subcutaneously into the dorsal flank of mice. Tumors were surgically dissected and measured and fixed in 4% PFA 3 weeks post injection, and embedded in paraffin. Sections were stained with hematoxylin and eosin. All protocols involving animal use were approved by the Institutional Animal Ethics Committee.

Embryoid Body Formation

Embryoid bodies were formed by hanging drop method (500 cells/20 μ L drop). Embryoid bodies were formed in ES media without LIF for 3 days. After 3 days these embryoid bodies were cultured on Matrigel-coated dishes for 6 days. Post 6 days, cells were collected for RNA isolation.

Co-immunoprecipitation

Co-immunoprecipitation was performed by incubating the cell lysate (lysed using 1% NP40 cell lysis buffer) with specific antibody and Dynabeads (Invitrogen). The supernatant was separated using Dynamag and analyzed by western blotting. Normal IgG was used as antibody control.

Membrane-Cytoplasmic Fractionation

For fractionation, cells were osmotically lysed in buffer (20 mM HEPES [pH 8], 0.1 mM KCl, 0.1 mM MgCl₂, and 20% glycerol), followed by passing of the lysate through an insulin syringe. The supernatant (cytoplasmic fraction) was collected by spinning at 14,000 rpm for 60 min. The membrane fraction was collected by lysing the pellet in buffer (20 mM HEPES [pH 8], 0.1 mM KCl,

0.1 mM MgCl₂, 20% glycerol, and 0.5% Triton-X 100), followed by spinning at 14,000 rpm, for 30 min.

Mathematical Modeling

TGF- β R and E-CAD are assumed to be present in membrane-bound, cytoplasmic, endosomal, and lysosomal forms. In addition, E-CAD is assumed to also exist in a recycling endosome. The presence of additional compartments, such as recycling endosome, or lumping/merging compartments, coupled with a compensatory change in the rate constants does not qualitatively change these results. The rates of interactions are assumed to follow mass-action kinetics. TGF- β ligand is assumed to be constantly available, and therefore the inhibition of *E-cad* expression by TGF- β signaling is assumed to be mediated by the level of the receptors present at the membrane, and consequently the downstream signaling. Inhibition is incorporated by including a Hill-like inhibitory term (with a coefficient of 2) to the zero-order formation kinetics. Inhibition of TGF- β signaling is modeled as an increase in the inhibition constant, which is equivalent to a reduction in the amount of membrane-bound TGF- β R available for inhibition. Based on these kinetics, a mass balance for each of the nine components of the system shown, leads to a system of 9 coupled ordinary differential equations, which include the effect of the 22 reactions and 28 parameters (equations and parameters are listed in Table S1).

The equations were integrated with the ode15s function of MATLAB version 9.2 and SimBiology version 5.6 with relative and absolute tolerance 10^{-8} until steady state was achieved, and this state was assumed to be the pre-treatment state of the system. The values were scaled to the maximum value following all the simulations (clathrin depletion, clathrin depletion with decreased TGF- β signaling).

Transferrin Uptake Assay

mESCs (20,000) were plated followed by transfection with *Cltc* esiRNAs or the mentioned plasmids after 24 hr. Next day, the cells were plated on 0.2% gelatin-coated glass coverslips. After 48 hr, cells were serum starved in plain knockout DMEM at 37°C. After 1 hr, cells were incubated with Transferrin-Alexa Fluor 488 (5 μ g/100 μ L) (no. 015-540-050, Jackson ImmunoResearch) for 10 min at 37°C, washed with acid wash buffer (0.2 M glycine, 0.15 M NaCl [pH 3.0]) for 30 s to remove surface-bound and non-specific transferrin. Cells were washed three times in PBS, fixed in 4% PFA, and imaged. All images were analyzed using ImageJ software (NIH). The total amount of internalized transferrin was quantified from cells as mean gray value, and background-subtracted values are represented from three independent experiments.

Statistical Analysis

Error bars represent mean \pm SD for three independent experiments ($n = 3$). Statistical significance, * $p < 0.05$; ** $p < 0.01$; *** $p < 0.001$, was determined by two-tailed Student's *t* test. mRNA expression is normalized to *GAPDH* and represented relative to non-targeting siRNA control. For comparing multiple groups of data, one-way ANOVA was used. If the *p* value for the comparison was < 0.05 , then individual groups were compared with each other using a *post-hoc* Tukey-Kramer test.



Apoptosis Analysis

Cells were fixed with 4% PFA for 10 min, followed by staining with Hoechst 33342 for 10 min. Cells were scored as apoptotic based on the presence of fragmented and/or condensed DNA, as described previously (Chakrabarti et al., 2004). As a positive control for apoptosis, cells were treated with camptothecin (6 μM) for 12 hr.

average cdf was generated to represent the Control cdf in a given plate. The largest difference between the cdf for each well and the Control cdf was then calculated for each well (kstest2). These differences for each of the individual control wells gave us a measure of differences that could occur purely by chance. The differences for all wells were normalized into a Z score as follows:

$$\text{Normalized difference} = \frac{\text{Individual well difference} - \text{Median of control well differences}}{\text{Median absolute deviation of control well difference}}$$

siRNA Screening

mESCs (2,000) were plated per well in a 96-well plate on day 0. On day 1, cells were transfected with siRNAs from the Dharmacon Membrane Trafficking siGENOME Library (GU-015500-05). None of the siRNAs were validated for their efficiency at the time of screening. Each well received a pool of four siRNAs against a single gene. At the time of transfection, cells were shifted to ESC medium minus LIF. Cells were fixed on day 4 and stained for AP (Vector Laboratories) and co-stained with DAPI. Each plate included ten control wells that were mock-transfected. Five were maintained in ESC medium and the other five in ESC minus LIF.

Image Analysis

All micrographs were analyzed using ImageJ software (NIH). Images were background-subtracted and quantified as mean gray values. For transferrin uptake assay, total cell fluorescence was quantified from three independent experiments. For E-CAD membrane/cytoplasmic quantification, total and cytoplasmic protein expressions were quantified from the middle section of the z stack. The membrane E-CAD expression was calculated by subtracting cytoplasmic from total expression, and represented as membrane versus cytoplasmic ratio from three independent experiments.

Screen Analysis

Every individual well of screen plates was imaged using the BD pathway 855, 4× objective, 5 × 5 matrix. All analysis was done using custom programs written in MATLAB (MathWorks). All images were read into MATLAB as two-dimensional matrices of pixel intensities. Images for the control wells were visually screened for the presence of imaging artifacts and wells with obvious artifacts like reflections were excluded. All pixels with intensity greater than a specified threshold value in the DAPI image were considered to be cells. In a subset of wells, the choice of this threshold value was visually checked using two criteria: (1) all chosen pixels did indeed correspond to cells and (2) no cells were omitted. A threshold value of 950 was found to satisfy the above criteria and was used for all wells in all plates. Once pixels corresponding to cells were identified, the locations of these pixels were transferred to the Texas Red image and a cumulative distribution function (cdf) of the intensities of these pixels was calculated using ecdf (MATLAB function) for each well. The pixel values for all of the control wells (ESCs–LIF) in a given plate were combined and an

Wells with a Z score >2.5 or ≤2.5 were considered as wells that had significant changes in their cdf and the direction of change was analyzed to see if they had more or less Texas Red staining compared with the Control cdf.

SUPPLEMENTAL INFORMATION

Supplemental Information includes five figures and two tables and can be found with this article online at <https://doi.org/10.1016/j.stemcr.2018.11.018>.

AUTHOR CONTRIBUTIONS

D.S. and Y.V.N. conceived and designed the study. D.S. carried out the screening in Figure 1A. R.R. carried out the analysis for Figure 1A. C.G. did the modeling for Figures 3K and 3L. R.D.M. did experiments for Figure S1J and helped with Figure S2. All other experiments were performed by Y.V.N.. D.S., and Y.V.N. wrote the manuscript with help from R.R. and C.G. All authors read and approved the manuscript.

ACKNOWLEDGMENTS

The authors thank Richa Rikhy and Ayantika (IISER Pune) for help with image analysis; IISER Pune for access to imaging facilities; Amitabha Majumdar and Jomon Joseph for discussions; NCCS Experimental Animal Facility and Subramanyam lab for critical reading of the manuscript and feedback. This work was supported by an Intermediate Fellowship from The Wellcome Trust/DBT India Alliance (IA/I/12/1/500507) to D.S.; Y.V.N. is a recipient of a CSIR-SRF Fellowship; R.R. is supported by a DBT Ramalingaswami Fellowship (BT/HRD/35/02/2006).

Received: December 28, 2017

Revised: November 16, 2018

Accepted: November 19, 2018

Published: December 13, 2018

REFERENCES

Anton, R., Kestler, H.A., and Kühl, M. (2007). Beta-catenin signaling contributes to stemness and regulates early differentiation in murine embryonic stem cells. *FEBS Lett.* 581, 5247–5254.



- Bitoun, M., Durieux, A.-C., Prudhon, B., Bevilacqua, J.A., Herledan, A., Sakanyan, V., Urtizberea, A., Cartier, L., Romero, N.B., and Guicheney, P. (2009). Dynamin 2 mutations associated with human diseases impair clathrin-mediated receptor endocytosis. *Hum. Mutat.* **30**, 1419–1427.
- Chakrabarti, O., Veeraraghavalu, K., Tergaonkar, V., Liu, Y., Androphy, E.J., Stanley, M.A., and Krishna, S. (2004). Human papillomavirus type 16 E6 amino acid 83 variants enhance E6-mediated MAPK signaling and differentially regulate tumorigenesis by notch signaling and oncogenic Ras. *J. Virol.* **78**, 5934–5945.
- Chen, Y.-G. (2009). Endocytic regulation of TGF- β signaling. *Cell Res.* **19**, 58–70.
- Dambournet, D., Sochacki, K.A., Cheng, A.T., Akamatsu, M., Taraska, J.W., Hockemeyer, D., and Drubin, D.G. (2018). Genome-edited human stem cells expressing fluorescently labeled endocytic markers allow quantitative analysis of clathrin-mediated endocytosis during differentiation. *J. Cell Biol.* **217**, 3301–3311.
- De Renzis, S., Yu, J., Zinzen, R., and Wieschaus, E. (2006). Dorsal-ventral pattern of delta trafficking is established by a snail-tom-neuralized pathway. *Dev. Cell* **10**, 257–264.
- Di Guglielmo, G.M., Le Roy, C., Goodfellow, A.F., and Wrana, J.L. (2003). Distinct endocytic pathways regulate TGF-beta receptor signalling and turnover. *Nat. Cell Biol.* **5**, 410–421.
- Doherty, G.J., and McMahon, H.T. (2009). Mechanisms of endocytosis. *Annu. Rev. Biochem.* **78**, 857–902.
- Eichel, K., Jullié, D., and von Zastrow, M. (2016). β -Arrestin drives MAP kinase signalling from clathrin-coated structures after GPCR dissociation. *Nat. Cell Biol.* **18**, 303–310.
- Evans, M. (2011). Discovering pluripotency: 30 years of mouse embryonic stem cells. *Nat. Rev. Mol. Cell Biol.* **12**, 680–686.
- Evans, M.J., and Kaufman, M.H. (1981). Establishment in culture of pluripotential cells from mouse embryos. *Nature* **292**, 154–156.
- Fabrowski, P., Necakov, A.S., Mumbauer, S., Loeser, E., Reversi, A., Streichan, S., Briggs, J.A.G., and Renzis, S.D. (2013). Tubular endocytosis drives remodelling of the apical surface during epithelial morphogenesis in *Drosophila*. *Nat. Commun.* **4**, 2244.
- Fazio, T.G., Huff, J.T., and Panning, B. (2008). An RNAi screen of chromatin proteins identifies Tip60-p400 as a regulator of embryonic stem cell identity. *Cell* **134**, 162–174.
- Fei, T., Zhu, S., Xia, K., Zhang, J., Li, Z., Han, J.-D.J., and Chen, Y.-G. (2010). Smad2 mediates Activin/Nodal signaling in mesendoderm differentiation of mouse embryonic stem cells. *Cell Res.* **20**, 1306–1318.
- Ferguson, S.M., and De Camilli, P. (2012). Dynamin, a membrane-remodelling GTPase. *Nat. Rev. Mol. Cell Biol.* **13**, 75–88.
- Hayes, S., Chawla, A., and Corvera, S. (2002). TGF β receptor internalization into EEA1-enriched early endosomes: role in signaling to Smad2. *J. Cell Biol.* **158**, 1239–1249.
- Herskovits, J.S., Burgess, C.C., Obar, R.A., and Vallee, R.B. (1993). Effects of mutant rat dynamin on endocytosis. *J. Cell Biol.* **122**, 565–578.
- Ichida, J.K., Blanchard, J., Lam, K., Son, E.Y., Chung, J.E., Egli, D., Loh, K.M., Carter, A.C., Di Giorgio, F.P., Koszka, K., et al. (2009). A small molecule inhibitor of Tgf- β signaling replaces Sox2 in reprogramming by inducing nanog. *Cell Stem Cell* **5**, 491–503.
- Kawamura, N., Sun-Wada, G.-H., Aoyama, M., Harada, A., Takasuga, S., Sasaki, T., and Wada, Y. (2012). Delivery of endosomes to lysosomes via microautophagy in the visceral endoderm of mouse embryos. *Nat. Commun.* **3**, 1071.
- Kirchhausen, T., Owen, D., and Harrison, S.C. (2014). Molecular structure, function, and dynamics of clathrin-mediated membrane traffic. *Cold Spring Harb. Perspect. Biol.* **6**, a016725.
- Kittler, R., Surendranath, V., Heninger, A.-K., Slabicki, M., Theis, M., Putz, G., Franke, K., Caldarelli, A., Grabner, H., Kozak, K., et al. (2007). Genome-wide resources of endoribonuclease-prepared short interfering RNAs for specific loss-of-function studies. *Nat. Methods* **4**, 337–344.
- Kunath, T., Saba-El-Leil, M.K., Almousailleakh, M., Wray, J., Meloche, S., and Smith, A. (2007). FGF stimulation of the Erk1/2 signalling cascade triggers transition of pluripotent embryonic stem cells from self-renewal to lineage commitment. *Development* **134**, 2895–2902.
- Lamouille, S., Xu, J., and Derynck, R. (2014). Molecular mechanisms of epithelial–mesenchymal transition. *Nat. Rev. Mol. Cell Biol.* **15**, 178–196.
- Larue, L., Ohsugi, M., Hirchenhain, J., and Kemler, R. (1994). E-cadherin null mutant embryos fail to form a trophectoderm epithelium. *Proc. Natl. Acad. Sci. U S A* **91**, 8263–8267.
- Leckband, D.E., and de Rooij, J. (2014). Cadherin adhesion and mechanotransduction. *Annu. Rev. Cell Dev. Biol.* **30**, 291–315.
- Li, L., Wang, S., Jezierski, A., Moalim-Nour, L., Mohib, K., Parks, R.J., Retta, S.F., and Wang, L. (2010). A unique interplay between Rap1 and E-cadherin in the endocytic pathway regulates self-renewal of human embryonic stem cells. *Stem Cells* **28**, 247–257.
- Li, Z., Yang, C.-S., Nakashima, K., and Rana, T.M. (2011). Small RNA-mediated regulation of iPS cell generation. *EMBO J.* **30**, 823–834.
- Martin, G.R. (1981). Isolation of a pluripotent cell line from early mouse embryos cultured in medium conditioned by teratocarcinoma stem cells. *Proc. Natl. Acad. Sci. U S A* **78**, 7634–7638.
- McMahon, H.T., and Boucrot, E. (2011). Molecular mechanism and physiological functions of clathrin-mediated endocytosis. *Nat. Rev. Mol. Cell Biol.* **12**, 517–533.
- Mitchell, H., Choudhury, A., Pagano, R.E., and Leof, E.B. (2004). Ligand-dependent and -independent transforming growth factor- β receptor recycling regulated by clathrin-mediated endocytosis and Rab11. *Mol. Biol. Cell* **15**, 4166–4178.
- Miyabayashi, T., Teo, J.-L., Yamamoto, M., McMillan, M., Nguyen, C., and Kahn, M. (2007). Wnt/beta-catenin/CBP signaling maintains long-term murine embryonic stem cell pluripotency. *Proc. Natl. Acad. Sci. U S A* **104**, 5668–5673.
- Mote, R.D., Mahajan, G., Padmanabhan, A., Ambati, R., and Subramanyam, D. (2017). Dual repression of endocytic players by ESCC microRNAs and the Polycomb complex regulates mouse embryonic stem cell pluripotency. *Sci. Rep.* **7**, 17572.
- Murray, P., Prewitz, M., Hopp, I., Wells, N., Zhang, H., Cooper, A., Parry, K.L., Short, R., Antoine, D.J., and Edgar, D. (2013). The self-renewal of mouse embryonic stem cells is regulated by



- cell-substratum adhesion and cell spreading. *Int. J. Biochem. Cell Biol.* **45**, 2698–2705.
- Nanes, B.A., and Kowalczyk, A.P. (2012). Adherens junction turnover: regulating adhesion through cadherin endocytosis, degradation, and recycling. *Subcell. Biochem.* **60**, 197–222.
- Nieto, M.A., Huang, R.Y.-J., Jackson, R.A., and Thiery, J.P. (2016). EMT: 2016. *Cell* **166**, 21–45.
- Perez-Moreno, M., and Fuchs, E. (2006). Catenins: keeping cells from getting their signals crossed. *Dev. Cell* **11**, 601–612.
- Presley, J.F., Mayor, S., McGraw, T.E., Dunn, K.W., and Maxfield, F.R. (1997). Bafilomycin A1 treatment retards transferrin receptor recycling more than bulk membrane recycling. *J. Biol. Chem.* **272**, 13929–13936.
- Qin, H., Diaz, A., Blouin, L., Lebbink, R.J., Patena, W., Tanbun, P., LeProust, E.M., McManus, M.T., Song, J.S., and Ramalho-Santos, M. (2014). Systematic identification of barriers to human iPSC generation. *Cell* **158**, 449–461.
- Redmer, T., Diecke, S., Grigoryan, T., Quiroga-Negreira, A., Birchmeier, W., and Besser, D. (2011). E-cadherin is crucial for embryonic stem cell pluripotency and can replace OCT4 during somatic cell reprogramming. *EMBO Rep.* **12**, 720–726.
- Saffarian, S., Cocucci, E., and Kirchhausen, T. (2009). Distinct dynamics of endocytic clathrin-coated pits and coated plaques. *PLoS Biol.* **7**, e1000191.
- Scita, G., and Di Fiore, P.P. (2010). The endocytic matrix. *Nature* **463**, 464–473.
- Sinha, A., Khadilkar, R.J., S, V.K., Roychowdhury Sinha, A., and Inamdar, M.S. (2013). Conserved regulation of the Jak/STAT pathway by the endosomal protein asrij maintains stem cell potency. *Cell Rep.* **4**, 649–658.
- Soncin, F., Ward, C.M., Soncin, F., and Ward, C.M. (2011). The function of E-cadherin in stem cell pluripotency and self-renewal. *Genes* **2**, 229–259.
- Song, S., Eckerle, S., Onichtchouk, D., Marrs, J.A., Nitschke, R., and Driever, W. (2013). Pou5f1-dependent EGF expression controls E-cadherin endocytosis, cell adhesion, and zebrafish epiboly movements. *Dev. Cell* **24**, 486–501.
- Stavridis, M.P., Lunn, J.S., Collins, B.J., and Storey, K.G. (2007). A discrete period of FGF-induced Erk1/2 signalling is required for vertebrate neural specification. *Development* **134**, 2889–2894.
- Stephenson, R.O., Yamanaka, Y., and Rossant, J. (2010). Disorganized epithelial polarity and excess trophoblast cell fate in pre-implantation embryos lacking E-cadherin. *Development* **137**, 3383–3391.
- Subramanyam, D., Lamouille, S., Judson, R.L., Liu, J.Y., Bucay, N., Derynck, R., and Blesch, R. (2011). Multiple targets of miR-302 and miR-372 promote reprogramming of human fibroblasts to induced pluripotent stem cells. *Nat. Biotechnol.* **29**, 443–448.
- Tebar, F., Sorkina, T., Sorkin, A., Ericsson, M., and Kirchhausen, T. (1996). Eps15 is a component of clathrin-coated pits and vesicles and is located at the rim of coated pits. *J. Biol. Chem.* **271**, 28727–28730.
- Traub, L.M. (2009). Tickets to ride: selecting cargo for clathrin-regulated internalization. *Nat. Rev. Mol. Cell Biol.* **10**, 583–596.
- Wang, Y., Melton, C., Li, Y.-P., Shenoy, A., Zhang, X.-X., Subramanyam, D., and Blesch, R. (2013). miR-294/miR-302 promotes proliferation, suppresses G1-S restriction point, and inhibits ESC differentiation through separable mechanisms. *Cell Rep.* **4**, 99–109.
- Wandler, S.L., and Bilder, D. (2010). Endocytic internalization routes required for Delta/Notch signaling. *Curr. Biol.* **20**, 538–543.
- Xu, J., Lamouille, S., and Derynck, R. (2009). TGF- β -induced epithelial to mesenchymal transition. *Cell Res.* **19**, 156–172.
- Ying, Q.-L., Wray, J., Nichols, J., Batlle-Morera, L., Doble, B., Woodgett, J., Cohen, P., and Smith, A. (2008). The ground state of embryonic stem cell self-renewal. *Nature* **453**, 519.

Stem Cell Reports, Volume 12

Supplemental Information

**Clathrin-Mediated Endocytosis Regulates a Balance between Opposing
Signals to Maintain the Pluripotent State of Embryonic Stem Cells**

Yadavalli V. Narayana, Chetan Gadgil, Ridim D. Mote, Raghav Rajan, and Deepa Subramanyam

Title: Clathrin mediated endocytosis regulates a balance between opposing signals to maintain the pluripotent state of embryonic stem cells.

Authors: Yadavalli V. Narayana^{1,2}, Chetan Gadgil³, Ridim D. Mote¹, Raghav Rajan⁴ and Deepa Subramanyam^{1*}

Supplemental Information:

Fig. S1: Decrease in CME reduces transferrin uptake and pluripotency gene expression in mESCs (related to Fig. 1).

Fig. S2: Single mESCs with reduced CME form dispersed colonies compared to WT ESCs (related to Fig. 1).

Fig. S3: Depletion of surface E-CAD levels reduces mESC pluripotency (related to Fig. 2).

Fig. S4: Blocking either Dynamin-dependent endocytosis or lysosomal degradation increases TGF β /SMAD signaling (related to Fig. 3).

Fig. S5: Effect of *Cltc* knockdown in mESCs can be partially rescued by blocking MEK signaling (related to Fig. 5).

Table S1: Construction of a mathematical model for the inter-relationships between TGF β signaling, E-CAD and CLTC (related to Fig. 3).

Table S2: List of primers used in this study.

Supplemental Figure 1




Fig. S1: Decrease in CME reduces transferrin uptake and pluripotency gene expression in mESCs (related to Fig. 1):

A) Western blot showing levels of CLTC 72 hours post knockdown in mESCs transfected with NT siRNA or *Cltc* siRNA. B) Representative confocal micrographs showing transferrin uptake into mESCs, in cells transfected with NT siRNA or *Cltc* siRNA. Scale bar top panel 10 μ m; lower panel 25 μ m. C) Scatter plot showing quantitation of transferrin endocytosed into mESCs from panel B). * * * $p < 0.001$ by two-tailed students T-test. D) Representative confocal micrographs showing transferrin uptake in mESCs overexpressing the *K44A Dnm (K44A)*, Scale bar 25 μ m. E) Scatter plot showing the quantitation of transferrin uptake in mESCs overexpressing *K44A Dnm (K44A)*. F) Western blots showing levels of pluripotency markers post 72 hours of *Cltc* knockdown, or *K44A Dnm (K44A)* expression in mESCs. G) Bar graph showing the expression of differentiation marker gene expression in *Cltc* depleted (normalized to NTi transfected cells), or *K44A Dnm (K44A)* (normalized to empty vector transfected cells) expressing mESCs. Control is shown as a dotted line at 1. H) Bar graph showing the expression of pluripotency marker genes post *Cltc* knockdown in R1 mESCs. I) Bar graph showing the expression of differentiation marker genes in *Cltc* depleted R1 mESCs. J) Bar graph showing quantitation of apoptotic cells post knockdown of *Cltc*. K) Bar graph showing the size of teratomas derived from mESCs stably expressing either the scrambled control shRNA (SCi) or *Cltc* shRNA (*Cltc*i). L) Micrograph showing the histology of teratomas derived from mESCs expressing either the scrambled control shRNA or *Cltc* shRNA. Arrowheads depict structures representing different germ layers. Ect- ectoderm; Me- mesoderm; En- endoderm. Error bars represent mean \pm S.D from three independent experiments (N=3). * $p < 0.05$; * * $p < 0.01$; * * * $p < 0.001$ by two-tailed Students T-test.

Supplemental Figure 2




Fig. S2: Single mESCs with reduced CME form dispersed colonies compared to WT ESCs (related to Fig. 1):

Representative micrographs showing colony formation from single mESCs transfected with either non-targeting siRNA (NTi), siRNA targeting *Cltc* (*Cltci*), control vector, vector expressing *K44A Dnm*, scrambled shRNA (shScr), or shRNA targeting *Cltc* (sh*Cltc*) over a period of 4 days. Loss of CME through the loss of *Cltc* or the expression of *K44A Dnm* results in loose, dispersed colonies. Scale bar represents 10µm. Single mESCs transfected as indicated, were plated in 96 well plates in ES cell medium. The same cell was imaged every 24 hours over a period of 4 days.

Supplemental Figure 3




Fig. S3: Depletion of surface E-CAD levels reduces mESC pluripotency (related to Fig. 2):

A) Western blot showing E-CAD levels upon knockdown of *Cltc* in R1 mESCs B) Western blot showing presence of E-CAD in the membrane vs cytoplasmic compartments post fractionation, from *Cltc*-depleted mESCs. C) IP-Western blot showing interaction of E-CAD with AP2 α in mESCs. D and E) Representative confocal micrographs showing co-localization between E-CAD and CLTC; scale bar 10 μ m (D); and E-CAD and RAB11, scale bar 10 μ m in R1 mESCs (E). F and G) Representative confocal micrographs showing minimal, to no co-localization between (F) E-CAD and RAB7; and G) E-CAD and LAMP2, scale bar 25 μ m. H) Representative micrographs showing co-localization of E-CAD with the recycling endosomal marker, RAB11, in mESCs treated with EDTA, scale bar top panel 10 μ m; lower panel 25 μ m. I) Quantitation of E-CAD levels, membrane vs cytoplasmic; in the presence of EDTA. J) Graph showing levels of pluripotency marker gene expression by qRT-PCR analysis in mESCs treated with EDTA. K) Western blot showing levels of RAB11 post knockdown using an shRNA against *Rab11*. Error bars represent mean \pm S.D from three independent experiments (N=3).; * * p < 0.01; * * * p < 0.001 by two-tailed Students T-test.

Supplemental Figure 4




Fig. S4: Blocking either Dynamin-dependent endocytosis or lysosomal degradation increases TGF β /SMAD signalling (related to Fig. 3):

A) Graph showing levels of *E-cad* transcript as determined by qRT-PCR analysis upon expression of *K44A Dnm (K44A)* in mESCs. B) Western blot showing E-CAD levels in the presence of *K44A Dnm (K44A)* in mESCs. C) Western blot showing TGF β R1 and phospho and total SMAD2/3 levels in the presence of *K44A Dnm (K44A)* in mESCs. D) Graph showing levels of indicated transcripts as determined by qRT-PCR analysis upon expression of *K44A Dnm (K44A)* in mESCs. E) Western blot showing levels of TGF β R1 in *Cltc*-depleted R1 mESCs. F) Western blot showing phospho- and total SMAD2/3 levels in *Cltc*-depleted R1 mESCs. G) Representative confocal micrographs showing co-localization between TGF β R1 and CLTC in R1 mESCs, scale bar 25 μ m. H) Representative confocal micrographs showing co-localization between TGF β R1 and RAB7 in R1 mESCs, scale bar 7.5 μ m. I) Representative confocal micrographs showing little to no co-localization between TGF β R1 and RAB11 in mESCs, scale bar 25 μ m. J) Western blot showing levels of RAB7 protein post knockdown of *Rab7* in mESCs. K) Western blots showing E-CAD and LC31/2 levels in mESCs upon *Rab7* knockdown. L) Western blot showing LC31/2 levels in the presence of chloroquine (Chq). M and N) Western blots showing increased M) TGF β R1 and N) phospho- and total SMAD2/3 levels upon treatment of mESCs with chloroquine. O) Western blot showing E-CAD levels in mESCs upon treatment with chloroquine. Error bars represent mean \pm S.D from three independent experiments (N=3). * $p < 0.05$; ** $p < 0.01$; *** $p < 0.001$ by two-tailed Students T-test.

Supplemental Figure 5




Fig. S5: Effect of *Cltc* knockdown in mESCs can be partially rescued by blocking MEK signalling (related to Fig. 5):

A) Western blot showing the interaction between E-CAD and β -CATENIN following immunoprecipitation. B) Western blot showing increased phospho- β -CATENIN and reduced total β -CATENIN levels in mESCs upon knockdown of *Cltc*. C) Western blot showing the interaction of E-CAD and ERK1/2 following immunoprecipitation. D) Confocal micrograph showing the co-localization of E-CAD and ERK1/2 in mESCs. Scale bar 25 μ m. E) Western blot showing increased pERK1/2 levels upon knockdown of *Cltc*. F) qRT-PCR analysis showing relative expression of pluripotency markers in mESCs (control or *Cltc* knockdown) grown in 2i medium containing PD0325901 (MEK inhibitor) and CHIR99021 (GSK3 β inhibitor). G) qRT-PCR analysis showing relative expression of pluripotency markers in mESCs (control or *Cltc* knockdown) grown in 1i medium. PD- PD0325901 (MEK inhibitor); CHIR- CHIR99021 (GSK3 β inhibitor). Error bars represent mean \pm S.D from three independent experiments (N=3). * $p < 0.05$; * * $p < 0.01$; by two-tailed Students T-test. For S4G one-way ANOVA with post-hoc Tukey-Kramer test was used.

Table S1: Construction of a mathematical model for the inter-relationships between TGFβ signaling, E-cad and Cltc (related to Fig. 3):

Model Equations: The equations arise from a mass balance for each model component. For instance, the cytoplasmic TGFβr (Tc) concentration:

- (i) Decreases because of transport to the membrane through a first-order process (ReactionFlux1 in the Matlab formulation below);
- (ii) Increases due to transfer from the membrane (ReactionFlux2)
- (iii) Increase due to formation (unregulated, zero-order; ReactionFlux 19)
- (iv) Decreases because of degradation through a first-order process (ReactionFlux 21)

The rate of change of concentration is the net rate of increase when the rates of processes due to which Tc decreases are subtracted from the rates of processes due to which Tc increases.

This leads to a differential equation, with rates for (i)-(iv) sequentially represented by the four terms on the right-hand side of the equation below.

$$\frac{dTc}{dt} = -k_{TcTm}T_m + k_{TmTc}T_c + k_{fTc} - k_{dTc}T_c$$

Similar equations are formulated for each of the other components. The output from Matlab (Simbiology) is listed below, which will enable an exact replication of the results presented in the main text.

ODEs:

$$d(Tc)/dt = 1/Cell*(-ReactionFlux1 + ReactionFlux2 + ReactionFlux19 - ReactionFlux21)$$

$$d(Tm)/dt = 1/Cell*(ReactionFlux1 - ReactionFlux2 - ReactionFlux7 + ReactionFlux8)$$

$$d(Em)/dt = 1/Cell*(ReactionFlux3 - ReactionFlux4 + ReactionFlux5 - ReactionFlux6 + ReactionFlux13 - ReactionFlux14)$$

$$d(Ec)/dt = 1/Cell*(-ReactionFlux3 + ReactionFlux4 + ReactionFlux20 - ReactionFlux22)$$

$$d(Te)/dt = 1/Cell*(ReactionFlux7 - ReactionFlux8 - ReactionFlux9 + ReactionFlux10)$$

$$d(Ee)/dt = 1/Cell*(-ReactionFlux5 + ReactionFlux6 - ReactionFlux11 + ReactionFlux12 - ReactionFlux15 + ReactionFlux16)$$

$$d(Tl)/dt = 1/Cell*(ReactionFlux9 - ReactionFlux10 - ReactionFlux17)$$

$$d(Er)/dt = 1/Cell*(ReactionFlux11 - ReactionFlux12 - ReactionFlux13 + ReactionFlux14)$$

$$d(El)/dt = 1/Cell*(ReactionFlux15 - ReactionFlux16 - ReactionFlux18)$$

Fluxes:

$$ReactionFlux1 = (ktctm*Tc)*Cell$$

$$ReactionFlux2 = (ktmtc*Tm)*Cell$$

$$ReactionFlux3 = (kemec*Ec)*Cell$$

$$ReactionFlux4 = (kecem*Em)*Cell$$

$$ReactionFlux5 = (keeem*Ee)*Cell$$

$$ReactionFlux6=(kemee*Em*(1+(clathrin/Kclathemee))/(1+Ca/Kca2))*Cell$$

$$ReactionFlux7=(ktmte*Tm*(1*(clathrin/Kclathtmte)))*Cell$$

$$ReactionFlux8 = (ktetm*Te)*Cell$$

$$ReactionFlux9 = (ktetl*Te)*Cell$$

$$ReactionFlux10 = (ktlte*Tl)*Cell$$

$$ReactionFlux11 = (keer*Ee)*Cell$$

$$ReactionFlux12 = (keree*Er)*Cell$$

$$ReactionFlux13 = (kerem*Er)*Cell$$

$$ReactionFlux14 = (kemer*Em)*Cell$$

$$ReactionFlux15 = (keeel*Ee)*Cell$$

$$ReactionFlux16 = (kelee*El)*Cell$$

$$ReactionFlux17 = (kdtl*Tl)*Cell$$

$$ReactionFlux18 = (kdel*El)*Cell$$

$$ReactionFlux19 = (kftc)*Cell$$

$$ReactionFlux20 = (kfec/(1+Tm^2/Kitmec^2))*Cell$$

$$ReactionFlux21 = (kdtc*Tc)*Cell$$

$$ReactionFlux22 = (kdec*Ec)*Cell$$

Parameter Values:

Ca = 1
 clathrin = 1
 ktctm = 1
 ktmtc = 0.01
 kemec = 0.01
 kecem = 0.01
 Kca = 0.1
 keeem = 0.1
 kemee = 0.1
 Kclathemee = 0.01
 Kca2 = 0.1
 ktmtc = 0.1
 Kclathmtc = 0.01
 Kca3 = 0.1
 ktetm = 1
 ktetl = 1
 kltte = 0.01
 keeer = 1
 keree = 0.1
 kerem = 1
 kemer = 0.1
 keeel = 0.1
 kelee = 0.01
 kdtl = 10
 kdel = 1
 kftc = 0.01
 kfec = 0.001
 Kitmec = 1e-05
 kdte = 1e-05
 kdec = 1e-05
 Cell = 1

Initial Conditions:

Tc = 0
 Tm = 0
 Em = 0
 Ec = 0
 Te = 0
 Ee = 0
 Tl = 0
 Er = 0
 El = 0

#	Type	Count
1	Compartments	1
2	Species	9
3	Reactions	22
4	Parameters	2 Model, 28 Kinetic Law
5	Rules	0
6	Events	0

Table S2: List of primers used in this study.

Gene	Forward primer	Reverse primer
<i>Oct4</i>	AAAGCCCTGCAGAAGGAGCTAGAA	AACACCTTTCCAAAGAGAACG
<i>Sox2</i>	ACTTTTGTCCGAGACCGAGAA	CGCGGCCGGTATTTATAATC
<i>Nanog</i>	GCTCAGCACCAGTGGAGTATCC	TCCAGATGCGTTCACCAGATAG
<i>Klf4</i>	GACCTCCTGGACCTAGACTTTA	GAAGACGAGGATGAAGCTGAC
<i>Gapdh</i>	AACAGCAACTCCCCTCTTC	CCTGTTGCTGTAGCCGTATT
<i>Cltc</i> esiRNA	GGGCGGGGGCAGAGCTGGTGTCTGT	GGGCGGGCAAACGCTGAGCAAGTGAGA
<i>E-cad</i>	AGAGAAGCCATTGCCAAGTAC	AACGAATCCCTCAAAGACCG
<i>Snai2</i>	ACACATTAGAACTCACACTGGG	TGGAGAAGGTTTTGGAGCAG
<i>Cdh2</i>	CTTCCTTGCTTCTGACAATGG	TGAGTTGGGTTCTGGAGTTTC
<i>Zeb1</i>	AGACTATTCTGATTCCCCAAGTG	CCTTCTGAGCTAGTGTCTTGTC
<i>Rab7</i> esiRNA	GGGCGGGCGGGCAAGCACTATAAGGAG	GGGCGGGCCCAGAAGTGAATCCGAAAA
<i>Tbra</i>	AGGTACCCAGCTCTAAGGAAC	CGAGGCTAGACCAGTTATCATG
<i>Gata6</i>	AGCAAGATGAATGGCCTCAG	CTCACCTCAGCATTCTACG
<i>Nestin</i>	AAGTTCCCAGGCTTCTCTTG	GTCTCAAGGGTATTAGGCAAGG
<i>Fgf5</i>	AGAGTGGGCATCGGTTTC	CTCGTATTCTACAATCCCCTG
<i>Fgf8</i>	TGTGGAGACCGATACTTTTGG	TTGTTCTCCAGCACGATCTC
<i>Eomes</i>	CCTCCGTA CTTGCTTCTACACTT	AAAGCCTATAGGAACTGTGACATCATAC
<i>Krt18</i>	CTCCCGAGATTACAACCACTAC	GTTCTGTCTCAAACCTGGTTCTG
<i>GFP</i> esiRNA	GGGCGGGTATGGTGAGCAAGGGCGAGGAG	GGGCGGGTTTACTTGTACAGCTCGTCCATG
<i>Snai1</i>	ACATCCGAAGCCACACG	GTCAGCAAAGCACGGTTG

Gene	shRNA sequence
<i>Cltc</i>	ACTCGAGTATCCGTAACAAGA
<i>Rab11a</i>	ATCATGCTGATAGTAACATGG